Clinical Trials Sponsored by Phenogen Sciences

Total 19278 results

Memorial Sloan Kettering Cancer Center
Phenogen Sciences

Recruiting

Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations

Genetic Testing | BRCA1/2

United States
Henogen

Completed

Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™

Hepatitis B

Belgium, Czech Republic, Hungary
Henogen

Withdrawn

Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease

Acute Graft Versus Host Disease

Netherlands
Henogen

Completed

Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule

Hepatitis B

Czech Republic
Henogen

Completed

Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Epstein Barr Virus (EBV) Infection

Belgium
Henogen
GlaxoSmithKline

Completed

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.

Hepatitis B

Belgium, Czech Republic, Hungary
Henogen
GlaxoSmithKline

Completed

Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination

Hepatitis B

Belgium, Czech Republic, Hungary
Henogen
GlaxoSmithKline

Completed

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.

Hepatitis B

Belgium, Czech Republic, Hungary
Philogen S.p.A.

Recruiting

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC)

Soft Tissue Sarcoma

Spain, Germany, France, Italy, Poland
Philogen S.p.A.

Active, not recruiting

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS (DOXO75)

Soft Tissue Sarcoma

United States
Philogen S.p.A.

Terminated

A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

Rheumatoid Arthritis

Switzerland, Germany, Italy
Philogen S.p.A.

Active, not recruiting

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer (Nivokin)

Non-small Cell Lung Cancer (NSCLC)

Switzerland
Philogen S.p.A.

Terminated

Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection

Italy, Germany
Philogen S.p.A.

Completed

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Breast Cancer | Solid Tumor | Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC)

Italy
Philogen S.p.A.

Completed

Intratumoral Administration of L19IL2/L19TNF

Malignant Melanoma, Skin

Italy
Philogen S.p.A.

Terminated

131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Italy
Philogen S.p.A.

Not yet recruiting

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (GLIOSTELLA)

Glioblastoma
Philogen S.p.A.

Recruiting

Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma (FLASH)

Soft Tissue Sarcoma

France, Spain, Germany, Italy, Poland
Philogen S.p.A.

Recruiting

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (DUNCAN)

Carcinoma, Basal Cell | Carcinoma, Cutaneous Squamous Cell

Germany, Poland, Switzerland
Philogen S.p.A.

Recruiting

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (FIBROSARC US)

Leiomyosarcoma

United States
Philogen S.p.A.

Recruiting

Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal)

Malignant Melanoma

Italy, France, Germany, Poland
Philogen S.p.A.

Completed

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON)

Glioma of Brain

Switzerland
Philogen S.p.A.

Completed

Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Italy
Philogen S.p.A.

Terminated

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Breast Cancer | Advanced Solid Tumor

Italy
Shenzhen Hemogen

Recruiting

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

β-thalassemia

China
Philogen S.p.A.

Recruiting

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors (FAPrimo)

Breast Cancer | Colorectal Cancer | Pancreas Adenocarcinoma | Oesophageal Cancer

Italy
Philogen S.p.A.

Not yet recruiting

Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment (DekaJoint)

Rheumatoid Arthritis
Philogen S.p.A.

Recruiting

L19IL2/L19TNF in Skin Cancer Patients (IntriNSiC)

Kaposi Sarcoma | Merkel Cell Carcinoma | BCC - Basal Cell Carcinoma | SCC - Squamous Cell Carcinoma | Keratoacanthoma of Skin | Malignant Adnexal Tumors of the Skin (MATS) | Tumors From Cutaneous T-cell Lymphoma (CTCL)

Spain, France, Italy
Philogen S.p.A.

Recruiting

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR)

Glioblastoma

France, Germany, Italy, Switzerland
Philogen S.p.A.

Recruiting

Safety and Early Signs of Efficacy of IL12-L19L19. (DODEKA)

Advanced Solid Tumor | Metastatic Solid Tumor

Italy, Germany, Switzerland
Philogen S.p.A.

Recruiting

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma (GLIOSUN)

Glioblastoma

Switzerland
Philogen S.p.A.

Recruiting

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (NeoDREAM)

Melanoma Stage IIIB/C

Spain, United States, Switzerland
Philogen S.p.A.

Withdrawn

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression (GLIOASTRA)

Glioblastoma
Philogen S.p.A.

Terminated

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Philogen S.p.A.

Terminated

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Myeloid Leukemia, Relapsed, Adult

Germany
Philogen S.p.A.

Active, not recruiting

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Metastatic Melanoma Stage IV

Italy, Germany
Philogen S.p.A.

Completed

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Advanced Solid Tumors Amenable to Anthracycline Therapy | Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy

Germany, Italy
Philogen S.p.A.

Completed

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Malignant Melanoma

Austria, Germany
Philogen S.p.A.

Completed

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Brain Metastases From Solid Tumors

Italy, United Kingdom
Philogen S.p.A.

Terminated

Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

Patients With Cancer

Italy, United Kingdom
Shenzhen Hemogen

Recruiting

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

β-thalassemia

China
Beijing Shenogen Biomedical Co., Ltd

Recruiting

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP) (BESTPOP)

Hepatocellular Carcinoma

China
Shenzhen Hemogen

Recruiting

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

α-thalassemia

China
Philogen S.p.A.
Boehringer Ingelheim

Completed

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (PHIBI)

Acute Myeloid Leukemia (AML) Relapse

Germany
Phytogen Medical Foods S.L.

Completed

Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™

Breast Cancer

Spain
Philogen S.p.A.
Eudax S.r.l.

Completed

A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Cancer

Italy
Philogen S.p.A.
Syneos Health

Completed

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Advanced Solid Tumours

Italy, Germany
Philogen S.p.A.
Eudax S.r.l.

Terminated

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Metastatic Melanoma

Switzerland, Italy, Austria, Germany
Cancer Institute and Hospital, Chinese Academy...
Beijing Shenogen Biomedical Co., Ltd

Completed

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Solid Tumors

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Shenogen Biomedical Co., Ltd

Unknown

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Metastatic Breast Cancer

China

3

Subscribe